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Rheumatoid arthritis (RA) is an archetypal, common, complex autoimmune disease with both genetic and
environmental contributions to disease aetiology. Two novel RA susceptibility loci have been reported
from recent genome-wide and candidate gene association studies. We, therefore, investigated the evidence
for association of the STAT4 and TRAF1/C5 loci with RA using imputed data from the Wellcome Trust Case
Control Consortium (WTCCC). No evidence for association of variants mapping to the TRAF1/C5 gene was
detected in the 1860 RA cases and 2930 control samples tested in that study. Variants mapping to the
STAT4 gene did show evidence for association (rs7574865, P 5 0.04). Given the association of the TRAF1/
C5 locus in two previous large case–control series from populations of European descent and the evidence
for association of the STAT4 locus in the WTCCC study, single nucleotide polymorphisms mapping to these
loci were tested for association with RA in an independent UK series comprising DNA from >3000 cases with
disease and >3000 controls and a combined analysis including the WTCCC data was undertaken. We conﬁrm
association of the STAT4 and the TRAF1/C5 loci with RA bringing to 5 the number of conﬁrmed susceptibility
loci. The effect sizes are less than those reported previously but are likely to be a more accurate reﬂection of
the true effect size given the larger size of the cohort investigated in the current study.
Rheumatoid arthritis [RA (MIM 180300)] is a chronic
inﬂammatory arthritis occurring in 0.8% UK population and
characterized by progressive destruction of synovial joints
(1). A strong genetic component to disease aetiology has
been determined with heritability estimates of 50–60% (2).
The major susceptibility loci are: (i) the HLA-DRB1 gene, in
which a group of alleles each sharing a common amino acid
sequence in the peptide-binding groove and collectively
referred to as the shared epitope, is associated with both sus-
ceptibility and severity to RA (3) and (ii) the protein tyrosine
 To whom correspondence should be addressed. Tel: þ44 1612751638; Fax: þ44 1612755043; Email: anne.barton@manchester.ac.uk
# 2008 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Human Molecular Genetics, 2008, Vol. 17, No. 15 2274–2279
doi:10.1093/hmg/ddn128
Advance Access published on April 22, 2008phosphatase 22 (PTPN22) gene, which is associated with sus-
ceptibility to RA (4). Together, they account for 50% of the
genetic susceptibility to disease in populations of European
descent, although, interestingly, variation across the PTPN22
gene does not appear to be associated with RA in Japanese
or Korean populations (5).
Recently, tremendous progress has been made in identifying
further RA susceptibility variants and this has been achieved
using both genome-wide association (GWA) and candidate
gene approaches. First, the Wellcome Trust Case Control Con-
sortium (WTCCC) study was a GWA that included 1860 RA
cases and 2930 controls and conﬁrmed association to the two
known susceptibility variants, HLA-DRB1 and PTPN22 (P ,
10
27) (6). In addition, nine other loci showed modest evidence
for signiﬁcance and association to one of these, a locus lying
between the OLIG3 and TNFAIP3 genes on chromosome 6q,
has been unequivocally replicated in UK and US populations
(7,8). Secondly, a GWA study in US and Swedish populations
reported association to the TRAF1/C5 locus and this has sub-
sequently been conﬁrmed by a separate study (9,10). Finally,
the results of a ﬁne-mapping strategy investigating candidate
genes mapping under a peak of linkage in US RA families
has identiﬁed another RA susceptibility locus mapping to the
STAT4 gene in US subjects, which has been subsequently con-
ﬁrmed in Swedish and Korean populations (11,12).
Many of the variants putatively associated with RA suscep-
tibility were not genotyped directly in the WTCCC study.
However, genotypes have been imputed using the data from
directly genotyped single nucleotide polymorphisms (SNPs)
nearby and from patterns of linkage disequilibrium inferred
from HapMap data. Hence, imputed genotypes are available
from the WTCCC study for all common HapMap SNPs and
this data provides an opportunity to explore the two candidate
RA susceptibility loci, STAT4 and TRAF1/C5, in this data set.
The aim of the current study was to look for evidence for
association of previously reported RA susceptibility loci in
the WTCCC data set and to validate the ﬁndings by direct gen-
otyping of SNPs mapping to these regions in an independent
cohort of 3418 cases and 3337 controls from the UK.
RESULTS
Imputed data
Imputed genotype frequencies conformed to Hardy–Weinberg
expectations in the control population and allele frequencies
were similar to those reported previously in European popu-
lations where data were available.
No difference in genotype frequencies was observed for the
SNPs mapping to the TRAF1/C5 locus, previously reported to
be associated with RA in other populations, in the UK
WTCCC series (Table 1). Nominal evidence for association
was observed for SNPs mapping to the STAT4 gene (Table 1).
Validation
The same SNPs were genotyped directly in an independent
series of 3418 RA cases and 3337 controls. Concordance
rate for duplicate samples was 99.5%. A Breslow Day test
was undertaken to investigate heterogeneity between the
samples recruited by the different centres but none was
observed for any of the SNPs (P . 0.1). Hence genotype
counts were combined across the centres and compared
between validation cases and validation controls. SNPs
Table 1. Imputed genotypes for RA cases and controls from WTCCC study
Locus RA cases Population controls OR (95% CI) Trend P
rs3761847 (TRAF1/C5) G/A 1/1 608 (32.7) 1/1 960 (32.7) 0.99 (0.91–1.07) 0.80
1/2 902 (48.5) 1/2 1410 (48.0)
2/2 348 (18.7) 2/2 565 (19.3)
rs10818488 (TRAF1/C5) A/G 1/1 578 (31.1) 1/1 920 (31.4) 1.00 (0.92–1.09) 0.93
1/2 911 (49.0) 1/2 1419 (48.4)
2/2 369 (19.9) 2/2 595 (20.3)
rs10760130 (TRAF1/C5) G/A 1/1 578 (31.1) 1/1 920 (31.4) 1.00 (0.92–1.09) 0.93
1/2 911 (49.0) 1/2 1419 (48.4)
2/2 369 (19.9) 2/2 595 (20.3)
rs10760129 (TRAF1/C5) T/C 1/1 578 (31.1) 1/1 920 (31.4) 1.00 (0.92–1.09) 0.93
1/2 911 (49.0) 1/2 1419 (48.4)
2/2 369 (19.9) 2/2 595 (20.3)
rs10181656 (STAT4) C/G 1/1 1050 (56.5) 1/1 1736 (59.1) 1.11 (1.01–1.22) 0.03
1/2 692 (37.2) 1/2 1047 (35.7)
2/2 117 (6.3) 2/2 151 (5.2)
rs8179673 (STAT4) T/C 1/1 1054 (56.7) 1/1 1742 (59.4) 1.11 (1.01–1.22) 0.04
1/2 689 (37.1) 1/2 1042 (35.5)
2/2 115 (6.2) 2/2 150 (5.1)
rs11889341 (STAT4) C/T 1/1 1092 (58.8) 1/1 1800 (61.3) 1.10 (1.00–1.22) 0.05
1/2 671 (36.1) 1/2 1010 (34.4)
2/2 95 (5.1) 2/2 125 (4.3)
rs7574865 (STAT4) G/T 1/1 1080 (58.1) 1/1 1782 (60.7) 1.11 (1.00–1.22) 0.04
1/2 675 (36.3) 1/2 1016 (34.6)
2/2 103 (5.5) 2/2 136 (4.6)
Data shown in n (%).
1, common allele, listed ﬁrst; 2, minor allele, listed second.
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signiﬁcantly associated with RA susceptibility in the vali-
dation cohort (Table 2), although effect sizes were lower
than had been reported in the previous, smaller studies.
Combined analysis
The imputed data from the WTCCC study were ﬁrstly
combined with those from the validation study to create a
combined sample of .5000 RA cases and 6000 controls
in order to allow robust estimates of the strengths of the
effect sizes for these two loci to be calculated. The four
SNPs mapping to each locus show strong correlation with
each other (r
2 between STAT4 SNPs ¼ .0.97; r
2 between
TRAF1/C5 SNPs ¼ 0.97). The largest effect size of the
SNPs mapping to the STAT4 locus arises from rs7574865
(OR 1.15, 95% CI 1.08, 1.22; P ¼ 1. 9   10
25) and this is
in line with previous studies. Of the four TRAF1/C5 SNPs
tested, rs10760130 showed the greatest statistical evidence
for association but the effect size was less than that of the
STAT4 locus (OR 1.09, 95% CI 1.03, 1.15; P ¼ 0.001). Sec-
ondly, a meta-analysis including both the WTCCC and vali-
Table 2. Validation of SNPs in independent data set and combined analysis (with WTCCC samples)
SNP Minor allele
a
and frequency
Validation study Combined analysis
Genotypes (cases
versus controls)
OR (95% CI) Trend-P Genotypes (cases
versus controls)
OR (95% CI) Trend-P
rs3761847
(TRAF1/C5)
A and 0.43 1073 (31.4) versus
1102 (33.0)
1.09 (1.02–1.17) 0.014 1681 (31.9) versus
2060 (32.9)
1.08 (1.00–1.11) 0.06
1612 (47.2) versus
1607 (48.2)
2514 (47.6) versus
3017 (48.1)
733 (21.4) versus 628
(18.8)
1081 (20.5) versus
1193 (19.0)
rs10818488
(TRAF1/C5)
G and 0.43 988 (29.0) versus 968
(31.9)
1.14 (1.06–1.22) 3.5   10
24 1566 (29.7) versus
1888 (31.6)
1.08 (1.02–1.13) 0.006
1687 (49.5) versus
1514 (49.9)
2598 (49.3) versus
2933 (49.1)
734 (21.5) versus 552
(18.2)
1103 (20.9) versus
1147 (19.2)
rs10760130
(TRAF1/C5)
A and 0.44 949 (27.9) versus 943
(31.1)
1.15 (1.07–1.23) 7.1   10
25 1527 (29.0) versus
1863 (31.2)
1.09 (1.03–1.15) 0.001
1693 (49.7) versus
1524 (50.2)
2604 (49.5) versus
2943 (49.3)
764 (22.4) versus 567
(18.7)
1133 (21.5) versus
1162 (19.5)
rs10760129
(TRAF1/C5)
C 0.44 957 (28.1) versus 946
(31.3)
1.15 (1.08–1.24) 6.5   10
25 1535 (29.2) versus
1866 (31.3)
1.09 (1.03–1.15) 0.002
1682 (49.4) versus
1516 (50.1)
2593 (49.2) versus
2935 (49.3)
765 (22.5) versus 563
(18.6)
1134 (21.5) versus
1158 (19.4)
rs10181656
(STAT4)
G and 0.22 1958 (57.3) versus
2051 (61.5)
1.17 (1.08–1.27) 1.3   10
24 3008 (57.0) versus
3787 (60.4)
1.14 (1.07–1.21) 4.0   10
25
1264 (37.0) versus
1139 (34.1)
1956 (37.1) versus
2186 (34.9)
196 (5.7) versus 147
(4.4)
313 (5.9) versus 298
(4.8)
rs8179673
(STAT4)
C and 0.22 1959 (57.3) versus
2051 (61.5)
1.17 (1.08–1.27) 1.2   10
24 3013 (57.1) versus
3793 (60.5)
1.14 (1.07–1.21) 3.9   10
25
1262 (36.9) versus
1140 (34.2)
1951 (37.0) versus
2182 (34.8)
197 (5.8) versus 146
(4.4)
312 (5.9) versus 296
(4.7)
rs11889341 and
(STAT4)
T and 0.22 1969 (57.6) versus
2057 (61.6)
1.16 (1.07–1.26) 2.4   10
24 3061 (58.0) versus
3857 (61.5)
1.14 (1.07–1.21) 2.7   10
25
1257 (36.8) versus
1134 (34.2)
1928 (36.5) versus
2144 (34.2)
192 (5.6) versus 146
(4.4)
287 (5.4) versus 271
(4.3)
rs7574865
(STAT4)
b
T and 0.22 1937 (57.0) versus
1860 (61.5)
1.17 (1.08–1.28) 1.4   10
24 3017 (57.4) versus
3642 (61.1)
1.15 (1.08–1.22) 1.9   10
25
1266 (37.2) versus
1024 (33.9)
1941 (36.9) versus
2040 (34.2)
196 (5.8) versus 140
(4.6)
299 (5.7) versus 276
(4.6)
aAllele assignments as per Ensembl (www.ensembl.org) release 49, March 2008, from sense strand.
bOnly genotyped in 3399 cases and 3024 controls.
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odds ratios (OR rs7574865 1.14, 95% CI 1.07, 1.22; OR
rs10760130 1.08, 95% CI 1.03, 1.14).
Stratiﬁcation by anti-cyclic-citrullinated peptide
antibody status
RA is a clinically heterogeneous disease and there has been
some speculation recently that it may comprise two distinct
subgroups characterized by the presence or absence of anti-
bodies to citrullinated peptides recognized by anti-cyclic-
citrullinated peptide (CCP) antibodies. For example, the
association of carriage of shared epitope alleles of the
HLA-DRB1 gene, the major RA susceptibility gene, appears
conﬁned to anti-CCP-positive RA cases (reviewed in 13).
Hence, subgroup analysis was undertaken to explore whether
the associations of the STAT4 and TRAF1/C5 loci differed in
anti-CCP-positive and -negative individuals (Table 3). For
the STAT4 locus, the strength of the association was similar
in both subgroups. Although the TRAF1/C5 associations
appeared stronger in the anti-CCP-positive subgroup, an
effect, albeit smaller, was observed in the negative subgroup
and a direct comparison between anti-CCP-positive and
-negative subjects showed no statistically signiﬁcant evidence
for a difference between the subgroups (Table 3).
DISCUSSION
We have performed the best powered study, to date, investi-
gating putative RA susceptibility variants and have conﬁrmed
that both STAT4 and the TRAF1/C5 loci are associated with
RA susceptibility. This brings to 5 the number of conﬁrmed
RA susceptibility genes (HLA DRB1, PTPN22 and OLIG3/
TNFAIP3 in addition to the above two). The large sample
size allows robust estimates of the effect sizes to be inferred
and suggests that the remaining RA susceptibility genes may
have smaller effect sizes.
It is interesting to note that the TRAF1/C5 locus showed no
evidence for association in the WTCCC series but signiﬁcant
evidence for association in the larger validation cohort,
despite the similarity in allele and genotype frequencies
between the two UK control groups analysed. The linkage dis-
equilibrium across the region is high and conﬁdence scores for
the imputed genotypes exceeded 97%, suggesting that the
imputed genotypes from the WTCCC study should be accu-
rate. Indeed, although none of the previously associated
markers was genotyped directly in the WTCCC study, a
SNP in near-perfect correlation (rs10118357 r
2 ¼ 0.97 with
rs3761847 and r
2 ¼ 1 with rs10818488) was genotyped and
also failed to show evidence for association with RA in that
series (rs10118357 P ¼ 0.89).
The different effect sizes observed at the TRAF1/C5 locus in
different populations could be explained by population hetero-
geneity but we feel that this is unlikely because ﬁrst, clinical,
demographic and control allele frequencies were similar in the
two UK cohorts investigated, only one of which showed evi-
dence for association to the locus. Secondly, clinical and
demographic characteristics of the UK RA cases were
similar to the US, Swedish and Dutch series and, ﬁnally, the
frequency of other RA associated variants is similar across
all the populations studied. For example, published data on
Table 3. Stratiﬁcation by CCP-positive/negative subgroups in validation data set (controls are the same as shown in Table 2)
SNP Genotypes (CCPþ) Genotypes (CCP2) CCPþ versus controls
a CCP2 versus controls
a
OR (95% CI) Trend-P OR (95% CI) Trend-P
rs3761847 (TRAF1/C5) 257 (32.4) 166 (34.2) 1.09 (0.97–1.21) 0.14 1.05 (0.91–1.20) 0.51
359 (45.3) 212 (43.6)
177 (22.3) 108 (22.2)
rs10818488 (TRAF1/C5) 359 (29.6) 190 (30.8) 1.10 (1.00–1.21) 0.046 1.08 (0.95–1.22) 0.23
605 (49.8) 299 (48.5)
250 (20.6) 128 (20.7)
rs10760130 (TRAF1/C5) 342 (28.2) 185 (30.0) 1.12 (1.02–1.23) 0.018 1.08 (0.96–1.22) 0.22
609 (50.3) 300 (48.6)
260 (21.5) 132 (21.4)
rs10760129 (TRAF1/C5) 346 (28.5) 186 (30.1) 1.12 (1.02–1.23) 0.017 1.08 (0.96–1.22) 0.20
606 (50.0) 299 (48.5)
261 (21.5) 132 (21.4)
rs10181656 (STAT4) 451 (56.9) 279 (57.4) 1.15 (1.01–1.31) 0.03 1.21 (1.03–1.41) 0.02
305 (38.5) 173 (35.6)
37 (4.7) 34 (7.0)
rs8179673 (STAT4) 452 (57.0) 279 (57.4) 1.15 (1.01–1.30) 0.04 1.21 (1.03–1.41) 0.02
304 (38.3) 173 (35.6)
37 (4.7) 34 (7.0)
rs11889341 (STAT4) 451 (56.9) 280 (57.6) 1.15 (1.01–1.31) 0.04 1.20 (1.03–1.40) 0.02
307 (38.7) 173 (35.6)
35 (4.4) 33 (6.8)
rs7574865 (STAT4) 674 (55.7) 347 (56.2) 1.20 (1.07–1.34) 0.0014 1.21 (1.05–1.40) 0.0088
475 (39.2) 232 (37.6)
62 (5.1) 38 (6.2)
aA direct comparison of CCPþ versus CCP2 samples showed that there was no signiﬁcant difference between these two groups.
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sizes are similar across the two UK cohorts, the US and
Dutch series (6,7,14,15).
A more likely explanation of the differences of effect seen
across the different cohorts is that the effect size at this locus is
very modest, and it is, therefore, not surprising that the SNPs
will be associated in some, but not all, studies. Surprisingly,
this locus was ﬁrst identiﬁed from two independent studies
in which the initial sample sizes were much smaller than
those tested in the WTCCC study (9,10). This aptly demon-
strates the phenomenon of ‘winner’s curse’ in which effect
sizes are often over-estimated in the original studies. It also
demonstrates that failure to detect evidence for association,
even in a large case–control series like the WTCCC sample,
does not exclude a true but modest effect being present.
Indeed, if the true effect size is more like 1.09 and given the
risk allele frequency, the WTCCC study would only have
had 54% power to detect it at the 5% signiﬁcance level.
The evidence for association of SNPs mapping to the STAT4
gene is more consistent, in keeping with the larger effect size
conferred by this locus. The locus has previously been associ-
ated with both RA and systemic lupus erythematosus (SLE)
(11), suggesting that it may predispose to a number of auto-
immune diseases in the same way as the PTPN22 functional
variant has been shown to. In fact, the strength of the associ-
ation may be more pronounced in SLE. Further exploration in
other autoimmune diseases is now warranted.
Sequencing and ﬁne mapping studies will be required to
identify the most likely causal polymorphisms in these loci.
However, the strong genetic correlation of the SNPs in both
the STAT4 and TRAF1/C5 regions mean that genetic studies
alone will be unlikely to identify the causal variant. Functional
studies will be necessary to determine which the disease
variant is and how it contributes to the development of RA
but already it is possible to hypothesize a potential pathway:
previous evidence suggests that carriage of the PTPN22 sus-
ceptibility variant leads to a failure to delete autoreactive
T-cells, thereby predisposing to autoimmunity in general
(16). The presence of cigarette smoke, a recognized environ-
mental risk factor for RA, has been shown to result in the
citrullination of proteins (17) and the shared epitope alleles
of the HLA DRB1 gene are known to bind citrullinated epi-
topes more efﬁciently resulting in an exaggerated helper
T-cell response (18). Variation in either gene could predispose
to RA, therefore, by creating a permissive environment for an
up-regulated immune response. In turn, IL-12-induced acti-
vation of STAT4 has been shown to drive the production of
Th1 and Th17 rather than Th2 cells, and a Th1/Th17 mediated
inﬂammatory response is a hallmark of RA (19). The exagger-
ated Th1/Th17 response may mean that, in the presence of an
inﬂammatory trigger, the inﬂammatory response is
up-regulated leading to excess tumour necrosis factor (TNF)
production with resultant binding of TNF to its cell-surface
receptors TNFR1 and 2. Signalling via these receptors is
mediated via a number of pathways but the TRAF family of
receptors has been implicated, including TRAF1. In turn,
TRAF1 signalling has been reported to activate TNFAIP3
(A20)-induced apoptosis and activation of NF-kB (20). Vari-
ation in the genes or regulatory sequences at any stage of
this pathway could, therefore, predispose to RA by producing
a prolonged and sustained inﬂammatory response character-
istic of RA. Functional studies will be required to conﬁrm or
reﬁne this hypothesis and determine where environmental sus-
ceptibility factors interact.
The studies conﬁrm the utility of GWA approaches and
well-powered studies in unravelling the intricacies of
common, complex diseases such as RA. It is likely that a
number of other susceptibility loci of more moderate effect
sizes exist and these may only be revealed through combining
data or meta-analysis to generate sufﬁciently large sample
sizes to be conﬁdent of identifying their effects. However,
already key pathways are emerging and provide the possibility
of the development of further targeted therapies for this dis-
abling condition in future.
METHODS
Study design
Imputed genotypes for SNP markers previously reported to be
associated with RA were compared between 1860 RA cases
and 2930 controls from the WTCCC study. Previous work
suggests that, where linkage disequilibrium is high and conﬁ-
dence scores for imputed genotypes exceed 95%, the accuracy
of imputation in predicting actual genotype counts exceeds
98.4% (21). Variants mapping to the STAT4 and TRAF1/C5
genes previously reported to be associated with RA in other
populations, were genotyped in an independent UK sample
of 3418 cases with RA and 3337 controls. A combined analy-
sis was then undertaken including all the data from the
WTCCC and the validation cohort to provide a robust estimate
of effect sizes for these variants.
Cohorts
All subjects were white Caucasians and all cases satisﬁed 1987
ACR classiﬁcation criteria for RA, modiﬁed for genetic
studies. Both cohorts have been described previously but
brieﬂy:
WTCCC cohort. Cases (n ¼ 1860) with RA were recruited as
part of the arc National Repository of Family Material, from a
primary care-based inception cohort or from NHS Rheumatol-
ogy Clinics throughout the UK. Control data (n ¼ 2930) were
available for the 1958 birth cohort and from blood donors as
described and reported previously (6).
Validation data set. DNA was available from RA patients
recruited from six centres in the UK and ﬁve of these
centres also provided DNA samples from healthy controls:
Manchester 1372 cases and 924 controls (including 357 con-
trols from the 1958 birth cohort, not overlapping with those
samples tested in the WTCCC study); Shefﬁeld 979 cases
and 995 controls; Leeds, 1126 cases and 532 controls; Aberd-
een, 523 cases and 862 controls; Oxford, 736 cases and 536
controls; London, 327 cases, as reported previously. The
cases were from NHS Rheumatology Clinics throughout the
UK. Presence of autoantibodies [rheumatoid factor (RF) and/
or anti-CCP] was documented for a proportion of the patients.
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Imputed genotype data for the following SNPs were retrieved
from the WTCCC Web site:
STAT4: rs7574865, rs10181656, rs8179673 and rs11889341
show high correlation (r
2) with each other, map to the STAT4
gene and have been associated following a ﬁne mapping study
of a peak of linkage in US samples and replicated in Swedish
and Korean cohorts (11,12);
TRAF1/C5: rs3761847, rs10818488, rs10760130, rs10760129
and rs2900180 map to the TRAF1/C5 locus and these SNPs
(or highly correlated proxies) have been associated with RA in
populations from the Netherlands, US and Sweden (9,10).
Genotyping and analysis
Genotyping of the same variants in an independent cohort of RA
cases and controls was undertaken using the Sequenom MassAr-
ray platform (Sequenom, Inc., San Diego, CA, USA). Negative
controlsandduplicatesamples wereincluded toensurethe accu-
racy of genotyping. Only those samples with a .90% success
rate and only those SNPs with a genotyping success rate of
.95% were included in the analysis. Allele and genotype fre-
quencies were compared between RA patients and population
controls using the trend test implemented in STATA. Combined
analysisofSNPsusingimputeddatafromtheWTCCCstudyand
the validation cohort was subsequently performed and, in this
combined group, stratiﬁcation analysis based on the presence
of anti-CCP antibodies was undertaken.
This study was approved by the North West Multicentre
Research Ethics Committee (MREC 99/8/84) and all subjects
provided informed consent.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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